



EDELWEISS PUBLICATIONS
OPEN ACCESS

Commentary

ISSN: 2638-812X

Diabetic Peripheral Neuropathies (DPNs) from Basic and Clinical Aspects

Hiroshi Bando^{1,2*}

Affiliation

¹Tokushima University/Medical Research, Tokushima, Japan

²Japan Low Carbohydrate Diet Promotion Association, Kyoto, Japan

* **Corresponding author:** Hiroshi Bando, Tokushima University/Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan, Tel: +81-90-3187-2485, Email: pianomed@bronze.ocn.ne.jp

Citation: Bando H. Diabetic Peripheral Neuropathies (DPNs) from basic and clinical aspects (2019) J Obesity and Diabetes 3: 36-38.

Received: Oct 14, 2019

Accepted: Oct 24, 2019

Published: Oct 30, 2019

Copyright: © 2019 Bando H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: Diabetic peripheral neuropathies, Distal symmetric polyneuropathy, Diabetic autonomic neuropathy, Orthostatic hypotension, Nerve conduction velocity.

Abbreviations: DPNs-Diabetic Peripheral Neuropathies, DSPN-Distal Symmetric Polyneuropathy, DAN-Diabetic Autonomic Neuropathy, OH-Orthostatic Hypotension, NCV-Nerve Conduction Velocity, DPN-Diabetic Polyneuropathy, SNCV-Sural Nerve Conduction Velocity, SNAP-Sural Nerve Action Potential, UKPDS-UK Prospective Diabetes Study, ACCORD-Action to Control Cardiovascular Risk in Diabetes, CGM-Continuous Glucose Monitoring, T1DM and T2DM-Type 1 and 2 Diabetes Mellitus.

Diabetes has been one of the crucial diseases worldwide, which has to be controlled adequately for long years. It has three diabetic complications of micro-angiopathy such as neuropathy, retinopathy and nephropathy. Among them, Diabetic Peripheral Neuropathies (DPNs) are most prevalent to manage in primary care setting. In this article, recent topics concerning DPNs are introduced [1].

DPNs have a variety of symptoms and signs, then DPNs are often described in plural forms [2]. DPNs are classified into two categories, which are local and general. The former includes mononeuropathy and multifocal neuropathy. The latter includes diabetic polyneuropathy (DPN) and others. DPN has Distal Symmetric Polyneuropathy (DSPN) and Diabetic Autonomic Neuropathy (DAN) [2]. For examples, DSPN shows bilateral numbness of extremities and DAN shows Orthostatic Hypotension (OH).

What are DSPN and DAN like in clinical settings? We have been treating lots of diabetic patients for many years. Two conditions would be shown which are easy to understand. One is the research for DSPN, in which Sural Nerve Conduction Velocity (SNCV) and Sural Nerve Action Potential (SNAP) were measured in patients with Diabetes Mellitus (DM), Hemodialysis (HD) and control r [3]. In our study, there were four groups, which are 1) Both DM/HD, 2) DM only, 3) HD only, 4) control. The results of SNCV and SNAP showed from abnormal to normal in group 1,2,3,4, respectively, in this order [3].

Another is the situation of DAN with severe status of symptom. The case is 58 year-old man with neuropathy, retinopathy, nephropathy and remarkable OH. When he was lying position, his Blood Pressure (BP) was 164/98 mmHg. As he changed to sit on the bed, BP decreased to 140/82 mmHg. Just after standing up with 4-5 steps, his BP suddenly decreased to 98/56 mmHg associated with prompt dizziness and almost faint and unconsciousness due to OH. These phenomenon would be from typical DAN.

Author and colleagues have continued clinical practice and research for patients with Type 1 and 2 Diabetes Mellitus (T1DM, T2DM). Especially, we reported the clinical comparison of Low Carbohydrate Diet (LCD) and Calorie Restriction (CR) in T2DM. Furthermore, investigation of Latent Autoimmune Diabetes in Adults (LADA) was reported in T1DM [4-6].

In both of T1DM and T2DM, clinically important management would be Glycemic Control (GC) in the case of various situations. There was a study between the degree of GC and diabetic neuropathy [7]. It showed rather equivocal effect of DPNs for intensive GC in T2DM, which was from non-optimized HbA1c values [7]. The optimum GC values have not been shown for improving neuropathy results in T2DM by randomized trials [8].

On contrast, almost normal range of GC for more than 20 years prevented DPN in T1DM [9]. In the case of poorly controlled T2DM, Insulin-Providing Agents (IPAs) cannot bring normalization of HbA1c for long years because of potential severe hypoglycemia [8]. Consequently, the beneficial effect for normal range of HbA1c without hypoglycemia to Neuropathy Outcome Measures (NOMs) have not been studied in T2DM.

In addition to mean value of GC, Glycemic Variability (GV) [10] and metabolic various memories would influence DPN and also diabetic microangiopathies. Further, Impaired Glucose Tolerance (IGT) may exacerbate the pathophysiological changes of neuropathy as an indicator of small-fiber influence [11-13].

In the STENO-2 study, long-term rigorous glycemic control (A1c<6.5%) and multifactor intervention significantly reduced the risk of developing cardiovascular disease, nephropathy, retinopathy, and autonomic neuropathy. However, the risk of developing DSPN was not significant.



In order to prevent onset and progression of DSPN, it is important to maintain adequate GC and also GV. It is speculated from the pathology of IGT neuropathy [14,15].

There is a recently significant report that both neuropathy of small-diameter and large-diameter were significant related to strict GC around average HbA1c 6.1%. It could avoid not only hypoglycemia, but also GV, which were associated with stable management of body weight, blood pressure and lipid [16]. In the case of T2DM with relatively short duration, DPN could be improved by total care of GC and GV [16].

Regarding the evaluation of neuropathy, there has been a standard classification for the severity of neuropathy, which is the Toronto Consensus on Diabetic Neuropathies [17]. It considers a confirmed DPN as a combination of the presence of abnormal Nerve Conduction Velocity (NCV) and a symptom, or a sign. As a result, patients with NDS>2 and Sensory NCV of Sural Nerve (SNCV) <42 m/s were usually estimated as the presence of the neuropathy. This criteria have been applied for lots of reports about neuropathy [3].

In T2DM, intensive GC has been said to reduce diabetic micro vascular complications. Then, continuation of strict GC may prevent and ameliorate DPN. The intensive GC in T2DM is associated with a reduction in micro vascular complications. The strict GC may prevent and/or ameliorate the progress of DPN. However, Kumamoto Study showed that strict GC level as HbA1c 7.1% prevented NCV in T2DM [18]. In the UK Prospective Diabetes Study (UKPDS), the intensive and conventional GC as HbA1c 7.0% vs. 7.9% showed a similar effect on DPN [19]. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial showed that intensive care as HbA1c 6.3% prevented loss of ankle reflex and light-touch sensation but increased CVD-related mortality and severe hypoglycemia [8]. Consequently, these studies could not establish the optimum GC value for preventing the neuropathy deterioration in T2DM.

In order to obtain the beneficial effect in the light of diabetic complication, it would be necessary to maintain tight GC more than 3-5 years. In T2DM, chronic hyperglycemia has played a crucial role in progress of DPN. Furthermore, metabolic syndrome components would probably cause pathophysiological neuropathy. Glucose intolerance and obesity may have a role in progress of neuropathy. However, hyperlipidemia and hypertension showed equivocal results for neuropathy. In addition to GC, GV has been crucial factor to glucose variability. GV may show risk for progress of DPN apart from HbA1c values. From the cross-sectional investigation of T2M, GV showed a relationship with DPN value, which was studied by Continuous Glucose Monitoring (CGM). In these studies, GV data from CGM had been evaluated in the cross-sectional study associated with DPN data [20-25].

There is a recent significant report [26]. It was the neurophysiological comparison between two groups of subnormal level of HbA1c 6.5% and conventional treatment of HbA1c 7.2%. The former group showed formerly uncontrolled situation, but maintaining the HbA1c level for 4 years could bring the improvement of neurophysiological and some corneal nerve fiber measures. In contrast, the latter group showed the deteriorated data at the level of 7.2% [26]. Consequently, the standard level of diabetes care as HbA1c 7.0% does not seem to be enough for DPN.

Regarding diabetic neuropathy, recent research shows the several related genes, such as Aldose Reductase Gene (AKR1B1), Vascular Endothelial Growth Factor (VEGF), 5,10-Methylene-Tetrahydrofolate Reductase (MTHFR), Apolipoprotein E (APOE) and Angiotensin Converting Enzyme (ACE) genes. They would contribute significantly in the pathogenesis of DN, and may serve as biomarkers to predict future progress of neuropathy development and/or treatment response [27].

In summary, recent topics concerning diabetic neuropathy were described. Diabetic practice and various researches have been in progress for long, and this article would be expected to become useful reference for future development in diabetes.

References

1. Watterworth B and Wright TB. Diabetic peripheral neuropathy (2019) *Pain* 911-913. https://doi.org/10.1007/978-3-319-99124-5_194
2. Gibbons CH. Diabetes-related neuropathies (2019) *Small Fiber Neuropathy and Related Syndromes: Pain and Neurodegeneration*, Springer, Singapore 59-72. https://doi.org/10.1007/978-981-13-3546-4_6
3. Kato Y, Bando H, Fujikawa T, Narutaki M, Yamamoto M, et al. Influence of diabetes and hemodialysis against nerve conduction studies (2017) *J Gen Pract* 5: 343. <https://doi.org/10.4172/2329-9126.1000343>
4. Bando H, Ebe K, Muneta T, Bando M and Yonei Y. Investigation of fasting ratio of c-peptide/glucose and related markers in diabetes (2018) *Arch Diabetes Endocrine System* 1: 17-24.
5. Ebe K, Bando H, Muneta T, Bando M and Yonei Y. Homeostasis Model Assessment (HOMA) and M value in daily profile of glucose (2018) *POJ Clin Case Rep* 1: 1-7.
6. Bando H, Ebe K, Muneta T, Bando M and Yonei Y. Glucose variability for short period of Low Carbohydrate Diet (LCD) in diabetic patients with possible latent Autoimmune Diabetes In Adults (LADA) (2019) *Int Med* 1: 124-133. <https://doi.org/10.5455/im.302644275>
7. Ang L, Jaiswal M, Martin C and Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials (2014) *Curr Diab Rep* 14: 528. <https://doi.org/10.1007/s11892-014-0528-7>
8. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial (2010) *Lancet* 376: 419-430. [https://doi.org/10.1016/S0140-6736\(10\)60576-4](https://doi.org/10.1016/S0140-6736(10)60576-4)
9. Ziegler D, Behler M, Schroers-Teuber M and Roden M. Near-normoglycaemia and development of neuropathy: A 24-year prospective study from diagnosis of type 1 diabetes (2015) *BMJ Open* 5: e006559. <https://doi.org/10.1136/bmjopen-2014-006559>
10. Jin HY, Lee KA and Park TS. The impact of glycemic variability on diabetic peripheral neuropathy (2016) *Endocrine* 53: 643-648. <https://doi.org/10.1007/s12020-016-1005-7>
11. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history (2010) *Curr Diab Rep* 10: 276-282. <https://doi.org/10.1007/s11892-010-0120-8>
12. Chalmers J and Cooper ME. UKPDS and the legacy effect (2008) *N Engl J Med* 359: 1618-1620. <https://doi.org/10.1056/NEJMe0807625>
13. Asghar O, Petropoulos IN, Alam U, Jones W, Jeziorska M, et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance (2014) *Diabetes Care* 37: 2643-2646. <https://doi.org/10.2337/dc14-0279>
14. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, et al. Multifactorial intervention and cardiovascular disease in



- patients with type 2 diabetes (2003) *N Engl J Med* 348: 383-393.
15. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre-diabetic neuropathy (2006) *Diabetes Care* 29: 1294-1299. <https://doi.org/10.2337/dc06-0224>
 16. Ishibashi F, Taniguchi M, Kosaka A, Uetake H and Tavakoli M. Improvement in neuropathy outcomes with normalizing hba1c in patients with type 2 diabetes (2019) *Diabetes Care* 42: 110-118. <https://doi.org/10.2337/dc18-1560>
 17. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments (2010) *Diabetes Care* 33: 2285-2293. <https://doi.org/10.2337/dc10-1303>
 18. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study (1995) *Diabetes Res Clin Pract* 28: 103-117. [https://doi.org/10.1016/0168-8227\(95\)01064-k](https://doi.org/10.1016/0168-8227(95)01064-k)
 19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (1999) *The Lancet* 352: 837-853. [https://doi.org/10.1016/S0140-6736\(98\)07019-6](https://doi.org/10.1016/S0140-6736(98)07019-6)
 20. Giorgino F, Home PD and Tuomilehto J. Glucose control and vascular outcomes in type 2 diabetes: is the picture clear? (2016) *Diabetes Care* 39: 187-195. <https://doi.org/10.2337/dcS15-3023>
 21. Grisold A, Callaghan BC, and Feldman EL. Mediators of diabetic neuropathy: is hyperglycemia the only culprit? (2017) *Curr Opin Endocrinol Diabetes Obes* 24: 103-111. <https://doi.org/10.1097/MED.0000000000000320>
 22. Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, et al. Long-term glyceic variability and risk of adverse outcomes: a systematic review and meta-analysis (2015) *Diabetes Care* 38: 2354-2369. <https://doi.org/10.2337/dc15-1188>
 23. Yang CP, Li CI, Liu CS, Lin WY, Hwang KL, et al. Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM (2017) *Neurology* 88: 944-951. <https://doi.org/10.1212/WNL.0000000000003682>
 24. Xu F, Zhao LH, Su JB, Chen T, Wang XQ, et al. The relationship between glyceic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c (2014) *Diabetol Metab Syndr* 6: 139. <https://doi.org/10.1186/1758-5996-6-139>
 25. DeVries JH. Glucose variability: where it is important and how to measure it (2013) *Diabetes* 62: 1405-1408. <https://doi.org/10.2337/db12-1610>
 26. Ishibashi F and Tavakoli M. Impact of normoglycemia in reducing microvascular complications in patients with type 2 diabetes: a follow-up study (2018) *Front Endocrinol (Lausanne)* 9: 52. <https://doi.org/10.3389/fendo.2018.00052>
 27. Kallinikou D, Soldatou A, Tsentidis C, Louraki M, Kanaka-Gantenbein C, et al. Diabetic neuropathy in children and adolescents with type 1 diabetes mellitus: Diagnosis, pathogenesis, and associated genetic markers (2019) *Diabetes Metab Res Rev* e3178. <https://doi.org/10.1002/dmrr.3178>